Search Results

Progress demonstrates that BioHarvest’s Botanical Synthesis(TM) platform is capable of producing the targeted next-generation sweetening solution

Grant in Mexico marks a major milestone in global IP strategy, advancing protection of its VIVI Box platform across key international markets Highlights • Covers core innovations underpinning TempraMed’s VIVI Box™ multi-medication storage platform • Strengthens the Company’s intellectual property position in one of the world’s largest healthcare and consumer markets • Supports commercialization strategy and strategic engagement with appliance manufacturers across America’s premium refrigeration sector • Patent term extends through October 24, 2039

Argenx shares have fallen more than 13% after the surprise futility finding, which overshadowed a mid-stage celiac disease win for a separate asset acquired in the company’s $2.2 billion Forte Biosciences buy.

After one patient death prompted an FDA hold this spring, Newron Pharmaceuticals has now shared that a total of four fatalities have been recorded among participants receiving its schizophrenia candidate. A fifth death was recorded among those taking the placebo.